Literature DB >> 12065853

Ocular surface changes induced by topical antiglaucoma monotherapy.

Barbara Cvenkel1, Alojz Ihan.   

Abstract

PURPOSE: To investigate the expression of inflammatory markers HLA-DR in impression cytology specimens from patients receiving topical antiglaucoma monotherapy.
METHODS: Impression cytology specimens were obtained from patients taking no topical medication (n = 13) and from primary open-angle glaucoma or ocular hypertensive patients taking one topical medication for at least 3 months (latanoprost n = 14; betaxolol n = 12; timolol n = 14). None of the patients had any signs of ocular surface inflammation as detected by slit-lamp examination, a normal Schirmer's test and tear breakup time. The expression of HLA-DR on epithelial cells and T lymphocytes was analysed by flow cytometry.
RESULTS: A significant increase in HLA-DR on epithelial cells in patients on monotherapy was detected (latanoprost p < 0.05; betaxolol p < 0.01; timolol p < 0.01). Although the duration of treatment differed significantly between individual groups, there was no significant correlation between the length of monotherapy and the expression of inflammatory markers by epithelial cells and T lymphocytes. In the latanoprost group, the increased expression of HLA-DR was associated with a shorter duration of treatment.
CONCLUSIONS: The flow-cytometric results indicate that administration of a single topical medication preserved with benzalkonium chloride, irrespective of type, for 3 months or more induced a significant degree of subclinical inflammation detected as increased expression of HLA-DR on conjunctival epithelial cells. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065853     DOI: 10.1159/000059624

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  7 in total

1.  [Glaucoma and corneal transplantation].

Authors:  G Geerling; M Müller; M Zierhut; T Klink
Journal:  Ophthalmologe       Date:  2010-05       Impact factor: 1.059

2.  Ocular Surface Changes in Primary Open Angle Glaucoma with Long Term Topical Anti Glaucoma Medication.

Authors:  A P Kamath; S Satyanarayana; Fea Rodrigues
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Comparative study of topical anti-allergic eye drops on human conjunctiva-derived cells: responses to histamine and IFN gamma and toxicological profiles.

Authors:  Aude Pauly; Françoise Brignole-Baudouin; Jean-Marc Guenoun; Luisa Riancho; Patrice Rat; Jean-Michel Warnet; Christophe Baudouin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-08-10       Impact factor: 3.117

4.  Inflammatory molecules in aqueous humour and on ocular surface and glaucoma surgery outcome.

Authors:  Barbara Cvenkel; Andreja Natasa Kopitar; Alojz Ihan
Journal:  Mediators Inflamm       Date:  2010-05-05       Impact factor: 4.711

5.  Brimonidine in the treatment of glaucoma and ocular hypertension.

Authors:  Louis B Cantor
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

6.  Conjunctival changes and inflammatory aspects in rabbits' conjunctivas induced by fixed combinations of prostaglandin analogues and timolol maleate.

Authors:  Nubia Vanessa Lima de Faria; Heloisa Helena Russ; Palloma Rose; Lucia Noronha; Paulo Augusto Mello; Fabiano Montiani-Ferreira; Sebastião Cronemberger Sobrinho
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-01-28

7.  Ocular surface evaluation in patients treated with a fixed combination of prostaglandin analogues with 0.5% timolol maleate topical monotherapy: a randomized clinical trial.

Authors:  Heloisa Helena Russ; Pedro Antônio Nogueira-Filho; Jeison de Nadai Barros; Nubia Vanessa Lima de Faria; Fabiano Montiani-Ferreira; José Álvaro Pereira Gomes; Paulo Augusto Arruda Mello
Journal:  Clinics (Sao Paulo)       Date:  2013-10       Impact factor: 2.365

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.